KB Partners and Samson Ventures Deliver $10.4M to SteadyMed
September 18, 2012
SteadyMed Therapeutics, a drug delivery therapeutics company with offices in San Francisco and Rehovot, Israel, has landed $10.4 million from existing investors KB Partners and Samson Ventures. The new capital will support the development and commercialization of SteadyMed's PatchPump technology, a disposable subcutaneous drug delivery system. Samson previously led the company's $2 million Series A round back in early 2009.